Trial Profile
An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Mar 2022
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Precocious puberty
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 03 Dec 2018 Status changed from recruiting to completed.
- 26 Feb 2018 Planned End Date changed from 27 Feb 2018 to 30 Sep 2018.
- 26 Feb 2018 Planned primary completion date changed from 27 Feb 2018 to 30 Sep 2018.